BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 35444290)

  • 1. Challenges and progress toward tumor-targeted therapy by systemic delivery of polymer-complexed oncolytic adenoviruses.
    Thambi T; Hong J; Yoon AR; Yun CO
    Cancer Gene Ther; 2022 Oct; 29(10):1321-1331. PubMed ID: 35444290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic antitumor effect mediated by a paclitaxel-conjugated polymeric micelle-coated oncolytic adenovirus.
    Kasala D; Lee SH; Hong JW; Choi JW; Nam K; Chung YH; Kim SW; Yun CO
    Biomaterials; 2017 Nov; 145():207-222. PubMed ID: 28869866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic administration of human mesenchymal stromal cells infected with polymer-coated oncolytic adenovirus induces efficient pancreatic tumor homing and infiltration.
    Na Y; Nam JP; Hong J; Oh E; Shin HC; Kim HS; Kim SW; Yun CO
    J Control Release; 2019 Jul; 305():75-88. PubMed ID: 31071373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioreducible polymer-mediated delivery of oncolytic adenovirus can attenuate antiviral immune response and concurrently enhance the induction of antitumor immune response to effectively prevent metastasis.
    Kasala D; Lee SH; Hong J; Oh E; Yoon AR; Yun CO
    Biomater Sci; 2022 Jul; 10(15):4293-4308. PubMed ID: 35766864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model.
    Na Y; Choi JW; Kasala D; Hong J; Oh E; Li Y; Jung SJ; Kim SW; Yun CO
    J Control Release; 2015 Dec; 220(Pt B):766-82. PubMed ID: 26471393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient lung orthotopic tumor-growth suppression of oncolytic adenovirus complexed with RGD-targeted bioreducible polymer.
    Kim J; Nam HY; Choi JW; Yun CO; Kim SW
    Gene Ther; 2014 May; 21(5):476-83. PubMed ID: 24598892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A hydrogel matrix prolongs persistence and promotes specific localization of an oncolytic adenovirus in a tumor by restricting nonspecific shedding and an antiviral immune response.
    Jung BK; Oh E; Hong J; Lee Y; Park KD; Yun CO
    Biomaterials; 2017 Dec; 147():26-38. PubMed ID: 28923683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual tumor targeting with pH-sensitive and bioreducible polymer-complexed oncolytic adenovirus.
    Moon CY; Choi JW; Kasala D; Jung SJ; Kim SW; Yun CO
    Biomaterials; 2015 Feb; 41():53-68. PubMed ID: 25522965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesenchymal Stem Cell-Mediated Delivery of an Oncolytic Adenovirus Enhances Antitumor Efficacy in Hepatocellular Carcinoma.
    Yoon AR; Hong J; Li Y; Shin HC; Lee H; Kim HS; Yun CO
    Cancer Res; 2019 Sep; 79(17):4503-4514. PubMed ID: 31289131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells.
    Hammer K; Kazcorowski A; Liu L; Behr M; Schemmer P; Herr I; Nettelbeck DM
    Int J Cancer; 2015 Aug; 137(4):978-90. PubMed ID: 25604186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymeric oncolytic adenovirus for cancer gene therapy.
    Choi JW; Lee YS; Yun CO; Kim SW
    J Control Release; 2015 Dec; 219():181-191. PubMed ID: 26453806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic efficacy of a systemically delivered oncolytic adenovirus - biodegradable polymer complex.
    Kim J; Li Y; Kim SW; Lee DS; Yun CO
    Biomaterials; 2013 Jun; 34(19):4622-31. PubMed ID: 23541109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatoma targeting peptide conjugated bio-reducible polymer complexed with oncolytic adenovirus for cancer gene therapy.
    Choi JW; Kim HA; Nam K; Na Y; Yun CO; Kim S
    J Control Release; 2015 Dec; 220(Pt B):691-703. PubMed ID: 26437261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor effect and safety profile of systemically delivered oncolytic adenovirus complexed with EGFR-targeted PAMAM-based dendrimer in orthotopic lung tumor model.
    Yoon AR; Kasala D; Li Y; Hong J; Lee W; Jung SJ; Yun CO
    J Control Release; 2016 Jun; 231():2-16. PubMed ID: 26951927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic Adenovirus Coated with Multidegradable Bioreducible Core-Cross-Linked Polyethylenimine for Cancer Gene Therapy.
    Choi JW; Nam JP; Nam K; Lee YS; Yun CO; Kim SW
    Biomacromolecules; 2015 Jul; 16(7):2132-43. PubMed ID: 26096567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity In Vitro and In Vivo.
    Doerner J; Sallard E; Zhang W; Solanki M; Liu J; Ehrke-Schulz E; Zirngibl H; Lieber A; Ehrhardt A
    Mol Cancer Ther; 2022 Mar; 21(3):460-470. PubMed ID: 35027480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer.
    Wang Q; Ma X; Wu H; Zhao C; Chen J; Li R; Yan S; Li Y; Zhang Q; Song K; Yuan C; Kong B
    Oncoimmunology; 2022; 11(1):2096362. PubMed ID: 35800156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis.
    Choi JW; Jung SJ; Kasala D; Hwang JK; Hu J; Bae YH; Yun CO
    J Control Release; 2015 May; 205():134-43. PubMed ID: 25575865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viral genome DNA/lipoplexes elicit in situ oncolytic viral replication and potent antitumor efficacy via systemic delivery.
    Kwon OJ; Kang E; Kim S; Yun CO
    J Control Release; 2011 Oct; 155(2):317-25. PubMed ID: 21699929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oligopeptide-modified poly(beta-amino ester)s-coated AdNuPARmE1A: Boosting the efficacy of intravenously administered therapeutic adenoviruses.
    Brugada-Vilà P; Cascante A; Lázaro MÁ; Castells-Sala C; Fornaguera C; Rovira-Rigau M; Albertazzi L; Borros S; Fillat C
    Theranostics; 2020; 10(6):2744-2758. PubMed ID: 32194832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.